Phase 1 Evaluation of Investigational Agent in Patients with Infectious Staphylococcus aureus Endocarditis

The primary objective of this Phase 1 study is to evaluate the safety and tolerability of a new investigational treatment in patients with **Staphylococcus aureus endocarditis**. This condition is a serious infection of the heart valves caused by the bacterium Staphylococcus aureus, which can lead to significant morbidity and mortality. Understanding the safety profile of the investigational treatment is crucial for determining its potential as a therapeutic option for this life-threatening infection.

The clinical trial focuses on participants diagnosed with **infectious Staphylococcus aureus endocarditis**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. The trial involves a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. Participants were selected based on criteria that are not disclosed in the available data. Lifestyle considerations such as diet, physical activity, or habits are not specified. The trial aims to gather insights from a diverse group of individuals within the specified age range, encompassing both genders and including those considered vulnerable.

The clinical trial is designed to evaluate the safety and efficacy of a treatment for **Staphylococcus aureus endocarditis**. This study is a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date is March 18, 2024, with an anticipated end date of September 30, 2025. Participants will be randomly assigned to either the treatment group or the control group, ensuring that neither the participants nor the investigators know which treatment is being administered, thus maintaining the double-blind nature of the study.

The trial will begin with an inclusion visit, also known as the screening visit, where potential participants will be assessed for eligibility based on predefined criteria. This visit will include a comprehensive review of the participant's medical history, a physical examination, and necessary laboratory tests to confirm the diagnosis of **infectious S. aureus endocarditis**. Following successful screening, eligible participants will be enrolled in the study.

Throughout the trial, participants will attend regular follow-up visits. These visits are scheduled to monitor the participants' health, assess the treatment's efficacy, and record any adverse events. The frequency and number of follow-up visits will be determined by the study protocol, ensuring consistent data collection and participant safety. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the treatment.

The expected length of participant involvement in the study will be determined by the duration of the trial, from the initial screening to the end-of-study visit. Participants may be withdrawn from the study early if they experience significant adverse effects, if they withdraw consent, or if they fail to comply with the study protocol. The trial's design and procedures are structured to ensure the collection of reliable data while prioritizing participant safety and well-being.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for both experimental and non-experimental treatments is not available in the provided data.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on March 18, 2024, with an estimated completion date of September 30, 2025. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, as well as the specific timepoints for these assessments, are not specified in the provided information. The trial's focus on efficacy is aligned with the objectives typical of a Phase 3 study, which generally aims to confirm the effectiveness of a treatment in a larger patient population. The trial's design and execution will adhere to rigorous standards to ensure the reliability and validity of the efficacy data collected.